PRA Health Sciences pioneers connecting clinical trial patients with their real-world data with Synoma
Pharmaceutical, biotech and other research sponsors can now connect their clinical studies to longitudinal real-world data – speeding up drug development and aligning with the 21st Century Cures Act.
RALEIGH, N.C., May 13, 2021 (GLOBE NEWSWIRE) PRA Health Sciences, Inc. (NASDAQ: PRAH) announced today an innovative tokenization solution using Synoma
®, PRA’s proprietary technology that allows for the generation of enhanced evidence for drug development. PRA’s solution makes it possible to connect clinical trial data and secondary data sets with privacy at the forefront. Today, three large pharmaceutical companies, along with several other pharmaceutical and biotech companies of all sizes, are using Synoma to link data and conduct analyses across their drug development portfolios.
13 may 2021
PRA Health Sciences pioneers connecting clinical trial patients with their real-world data with Synoma
Pharmaceutical, biotech and other research sponsors can now connect their clinical studies to longitudinal real-world data – speeding up drug development and aligning with the 21st Century Cures Act.
RALEIGH, N.C., May 13, 2021 (GLOBE NEWSWIRE) PRA Health Sciences, Inc. (NASDAQ: PRAH) announced today an innovative tokenization solution using Synoma
®, PRA’s proprietary technology that allows for the generation of enhanced evidence for drug development. PRA’s solution makes it possible to connect clinical trial data and secondary data sets with privacy at the forefront. Today, three large pharmaceutical companies, along with several other pharmaceutical and biotech companies of all sizes, are using Synoma to link data and conduct analyses across their drug development portfolios.
Share this article
Share this article
NEW YORK, May 13, 2021 /PRNewswire/ Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies:
PRA Health Sciences, Inc. (NASDAQ: PRAH) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to ICON plc. Under the terms of the transaction, PRA Health shareholders will receive $80.00 in cash and 0.4125 shares of ICON stock for each PRA Health share that they own.
WSFS Financial Corporation (NASDAQ: WSFS)
concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its merger with Bryn Mawr Bank Corporation. Under the terms of the agreement, stockholders of Bryn Mawr will receive 0.90 of a share of WSFS common stock for each share of Bryn Mawr common stock.
Share this article
Share this article
ResearchAndMarkets.com s offering.
The Global Clinical Trials Market was valued at USD51.25 billion in 2020 and is anticipated to reach USD77.20 billion by 2026, registering a CAGR of 7.10% in the next five years.
The market is driven by the outbreak of tropical and infectious diseases such as COVID-19, which has led to extensive clinical trials around the world in order to find the suitable treatment and vaccine.
Also, the digitization of clinical trials is anticipated to propel the growth of this market in the coming years.
Additionally, the increasing prevalence of chronic diseases and growing need for personalized drugs are some other key factors propelling the growth of the Global Clinical Trials Market. Governments in various economies are also providing favorable support for clinical trials in order to find the cure for deadly diseases like coronavirus. The increasing expenditure on R&D activities and rise in biotechnology firms i
Dekker was most recently vice president of finance at Louisville-based biotechnology company GlobeImmune Inc., where he held finance roles for more than 15 years. He replaces Brian Selby, who left after 14 years at Arca.
Graybill was most recently at Lakewood-based Terumo BCT, the blood and cell-technology arm of Tokyo-based medical-device maker Terumo Corp., where he held global clinical affairs and research for just more than six years. He also had stints at DaVita Inc. (NYSE: DVA), PRA Health Sciences Inc. (Nasdaq: PRAH) and Gilead Sciences Inc. (Nasdaq: GILD).
Arca, which is based in Westminster, is focused on cardiovascular treatments. Its lead drug candidate AB201 was first brought into clinical trials as an anti-blood clot agent for cardiac patients, but the company pivoted to researching AB201 as a possible treatment for severe bouts of COVID-19.